Vallano A, Artaza A, Arnau J M, Pou L, García L, Vidal X, Moreno U, Laporte J R
Servicio de Farmacovigilancia Clínica, Hospital General Vall d'Hebron, Barcelona.
Med Clin (Barc). 1991 Oct 12;97(12):446-8.
The evaluation of the determination of plasmatic concentrations of theophylline (PCT) in clinical practice is scarce. An observational study was carried out with the aim of discerning the reasons why PCT determinations are requested, the theophyllinemias obtained and the attitude of the medical staff in a hospital.
PCT determinations obtained in 113 patients over a period of 3 months were analyzed. Information concerning treatment and daily doses of theophylline, reasons for theophylline determination, apart from those included in the request for theophyllinemia determination, clinical history and treatment sheets were collected.
Treatment with theophylline had been indicated in 78 patients (69%) with chronic bronchitis, and 30 (26%) with asthma. All the patients received medication in addition to theophylline. Daily dosage (SD) was 734 (260) mg and the daily doses as to body weight (SD) was 11 (4) mg/kg/day. 188 DNPT were performed, however 22 (12%) were inadequate; of the remaining 166 PCT determinations 117 (69%) had been requested with no indication of insufficient clinical response, suspicion of undesirable effects or modifying factors of the pharmacokinetics of theophylline. The mean plasmatic concentration (SD) was 11.3 (7) micrograms/ml. PCT was infratherapeutic in 74 PCT determinations (44%), therapeutic in 73 (44%) and toxic in 19 (11%). Therapeutic concentrations were obtained in only 16 (35%) of the 45 patients in whom a second PCT determination had been carried out.
In this study scarce individualization in the indication of treatment and the doses of theophylline administered are observed. The reason for soliciting determination of theophyllinemia and dosage adjustment in terms of plasmatic concentrations are also commented upon.
临床实践中对茶碱血浆浓度测定(PCT)的评估较少。开展了一项观察性研究,旨在查明进行PCT测定的原因、所获得的茶碱血药浓度以及医院医务人员的态度。
分析了113例患者在3个月内的PCT测定结果。收集了有关茶碱治疗及每日剂量、除茶碱血药浓度测定申请中所列原因之外的茶碱测定原因、临床病史和治疗记录单等信息。
78例(69%)慢性支气管炎患者和30例(26%)哮喘患者接受了茶碱治疗。所有患者除茶碱外还接受了其他药物治疗。每日剂量(标准差)为734(260)mg,按体重计算的每日剂量(标准差)为11(4)mg/kg/天。共进行了188次PCT测定,但22次(12%)不充分;在其余166次PCT测定中,117次(69%)的测定申请没有临床反应不足、怀疑有不良反应或茶碱药代动力学改变因素的指征。平均血浆浓度(标准差)为11.3(7)微克/毫升。74次PCT测定(44%)血药浓度低于治疗水平,73次(44%)为治疗水平,19次(11%)为中毒水平。在进行第二次PCT测定的45例患者中,只有16例(35%)获得了治疗浓度。
本研究观察到在茶碱治疗指征和给药剂量方面个体化不足的情况。还对茶碱血药浓度测定申请原因及根据血浆浓度进行剂量调整的情况进行了评论。